Opportunity Information: Apply for PAR 17 275
The NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U44) opportunity (Funding Opportunity Number PAR-17-275) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding program aimed specifically at helping small businesses move stroke-related innovations into well-structured human studies. The focus is on generating practical, clinically meaningful evidence in areas where stroke still carries major unmet needs: preventing strokes, treating acute stroke, and improving recovery and rehabilitation after stroke. In plain terms, this announcement is designed for companies that already have a promising intervention or measurement approach and now need to test it rigorously in people, or to complete the critical validation work that makes a clinical trial ready to run.
A central feature of this FOA is its emphasis on clinical trials and trial-enabling biomarker or outcome measure studies. On the clinical trial side, the NIH is looking for both exploratory and confirmatory trials. Exploratory trials are generally earlier-stage studies meant to refine dosing, feasibility, safety, and preliminary signals of benefit, while confirmatory trials are intended to more definitively test whether an intervention works under robust clinical trial conditions. On the biomarker and outcome-measure side, the FOA supports validation studies that are "immediately preparatory to trials," meaning the work should directly support near-term clinical testing rather than open-ended discovery research. This can include validating a biomarker that can stratify patients, predict outcomes, monitor treatment response, or serve as a reliable outcome measure, as well as validating clinical endpoints or measurement tools that make stroke trials more precise and efficient.
The award uses a cooperative agreement mechanism (U44), which signals that NIH expects to have substantial involvement in how the project is carried out, rather than operating purely as a traditional investigator-led grant. Practically, this often means closer coordination with NIH program staff and, in this case, alignment with the NIH StrokeNet infrastructure. The FOA also highlights that projects will be milestone-driven. Milestones are concrete, pre-specified goals that function like go/no-go decision points, helping ensure that the work stays on track and that the funding supports programs that are progressing toward clear clinical deliverables. For small businesses, this structure can be helpful because it forces early clarity on development plans, operational readiness, and what success looks like at each stage of the clinical program.
Eligibility is limited to small business concerns, consistent with SBIR rules, which makes this opportunity distinct from typical academic clinical trial funding. Foreign institutions (non-U.S. entities) are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. However, the FOA notes that foreign components, as defined in the NIH Grants Policy Statement, may be allowed, which usually means a U.S. applicant might be able to include certain narrowly justified foreign activities if NIH policy requirements are met and the work is essential to the project. The key point is that the applicant organization must be an eligible U.S. small business, and applicants should be cautious about structuring any international involvement.
From an administrative standpoint, this is a discretionary federal funding opportunity under NIH within the health activity category, listed under CFDA number 93.853. The announcement was created on 2017-05-10, and the original closing date shown is 2018-01-05. The source data does not provide an award ceiling, expected award count, or other budget specifics in the excerpt provided, but the use of a U44 cooperative agreement and the explicit clinical trial focus indicate that NIH is aiming to support serious, execution-ready programs rather than purely conceptual work. Overall, the opportunity is best understood as a pathway for SBIR-eligible companies to leverage NIH StrokeNet and NIH oversight to run milestone-based clinical trials or to validate biomarkers and outcome measures that directly enable those trials in stroke prevention, treatment, and recovery.Apply for PAR 17 275
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
- This funding opportunity was created on 2017-05-10.
- Applicants must submit their applications by 2018-01-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH StrokeNet SBIR Clinical Trials and Biomarker Studies for Stroke (U44) - PAR-17-275
What is this funding opportunity?
This is an NIH Small Business Innovation Research (SBIR) funding opportunity focused on moving stroke-related innovations into well-structured human studies. It supports projects aimed at stroke prevention, acute stroke treatment, and stroke recovery/rehabilitation through clinical trials and trial-enabling biomarker or outcome-measure validation studies.
What is the official program name and funding opportunity number?
The opportunity is titled "NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U44)" with Funding Opportunity Number PAR-17-275.
Which NIH mechanism does this opportunity use?
It uses a cooperative agreement mechanism (U44), which means NIH expects substantial involvement in how the project is carried out, rather than operating purely as an investigator-led grant.
What types of projects does this FOA support?
The FOA supports two main project categories: (1) clinical trials (including exploratory and confirmatory trials), and (2) biomarker or outcome-measure studies that are immediately preparatory to clinical trials.
Does this opportunity support clinical trials?
Yes. A central feature of this FOA is its emphasis on conducting clinical trials in humans for stroke-related interventions.
What is the difference between exploratory and confirmatory trials under this FOA?
Exploratory trials are generally earlier-stage studies designed to refine dosing, feasibility, safety, and preliminary signals of benefit. Confirmatory trials are intended to more definitively test whether an intervention works under robust clinical trial conditions.
What kinds of biomarker studies are supported?
The FOA supports validation studies for biomarkers that directly enable near-term clinical testing. Examples described include biomarkers used to stratify patients, predict outcomes, monitor treatment response, or serve as a reliable outcome measure.
Are outcome measures and clinical endpoints eligible topics?
Yes. The FOA explicitly includes validation of clinical endpoints or measurement tools intended to make stroke trials more precise and efficient, as long as the work is immediately preparatory to trials.
Is open-ended discovery research a fit for this announcement?
Based on the description provided, the biomarker/outcome-measure work should not be open-ended discovery research. It should be trial-enabling and directly support near-term clinical testing.
What disease areas and stages of care are emphasized?
The focus areas are where stroke has major unmet needs: preventing strokes, treating acute stroke, and improving recovery and rehabilitation after stroke.
Who is eligible to apply?
Eligibility is limited to small business concerns, consistent with SBIR rules. This makes the opportunity distinct from typical academic clinical trial funding.
Can foreign institutions apply?
No. Foreign institutions (non-U.S. entities) are not eligible to apply under the terms described.
Are non-U.S. components of U.S. organizations allowed?
No. Non-U.S. components of U.S. organizations are also described as not eligible.
Are any foreign activities allowed at all?
The FOA notes that foreign components, as defined in the NIH Grants Policy Statement, may be allowed. In practical terms, that usually means a U.S. applicant might include narrowly justified foreign activities if NIH policy requirements are met and the work is essential to the project.
How does NIH involvement affect how the project is run?
Because this is a U44 cooperative agreement, NIH expects substantial involvement. Practically, that implies closer coordination with NIH program staff and alignment with NIH StrokeNet infrastructure.
What does it mean that projects are milestone-driven?
Milestone-driven means projects include concrete, pre-specified goals that act like go/no-go decision points. The intent is to keep the work on track and ensure funding supports programs progressing toward clear clinical deliverables.
Why are milestones important for small businesses?
As described, the milestone structure can help small businesses by forcing early clarity on development plans, operational readiness, and what success looks like at each stage of the clinical program.
Does this opportunity relate to NIH StrokeNet?
Yes. The FOA emphasizes alignment with the NIH StrokeNet infrastructure as part of how projects may be carried out under NIH involvement.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.853.
What is the funding category and general classification?
It is described as a discretionary federal funding opportunity under NIH, within the health activity category.
When was the announcement created and what closing date is shown?
The announcement was created on 2017-05-10, and the original closing date shown is 2018-01-05.
Are budget limits, award ceiling, or number of awards provided in the excerpt?
No. The excerpt explicitly states that it does not provide an award ceiling, expected award count, or other budget specifics.
What kind of company is this best suited for?
Based on the description, it is best suited for SBIR-eligible companies that already have a promising stroke-related intervention or measurement approach and now need rigorous testing in people, or need to complete critical validation work that makes a clinical trial ready to run.
What is the overall purpose of this FOA in plain terms?
In plain terms, it is designed to help small businesses generate practical, clinically meaningful evidence by running milestone-based stroke clinical trials or validating biomarkers/outcome measures that directly enable those trials.
Browse more opportunities from the same category: Health
Next opportunity: NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - No Independent Clinical Trials)
Previous opportunity: AHRQ Mentored Clinical Scientist Research Career Development Award (K08)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 17 275
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 17 275) also looked into and applied for these:
| Funding Opportunity |
|---|
| Uncovering the Causes, Contexts, and Consequences of Elder Mistreatment (R01) Apply for RFA AG 18 010 Funding Number: RFA AG 18 010 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21) Apply for PA 17 282 Funding Number: PA 17 282 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R21) Apply for PA 17 284 Funding Number: PA 17 284 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R01) Apply for PA 17 285 Funding Number: PA 17 285 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Academic Leadership Career Award (K07) Apply for PAR 17 287 Funding Number: PAR 17 287 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25) Apply for PAR 17 290 Funding Number: PAR 17 290 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (U34) Apply for RFA HL 18 008 Funding Number: RFA HL 18 008 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33) Apply for RFA AT 18 001 Funding Number: RFA AT 18 001 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) Apply for PAR 17 293 Funding Number: PAR 17 293 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (X01) Apply for RFA HL 18 009 Funding Number: RFA HL 18 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01) Apply for PA 17 291 Funding Number: PA 17 291 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R21) Apply for PA 17 292 Funding Number: PA 17 292 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans Resource Access (X01) Apply for PAR 17 294 Funding Number: PAR 17 294 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stakeholder Consultative Workshop in Guatemala Apply for NEWHEALTHACTIVITY Funding Number: NEWHEALTHACTIVITY Agency: Guatemala USAID-Guatemala City Category: Health Funding Amount: Case Dependent |
| Alcohol-Induced Effects on Tissue Injury and Repair (R01) Apply for PA 17 297 Funding Number: PA 17 297 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ National Research Service Award (NRSA) Institutional Research Training Grant (T32) Apply for RFA HS 17 011 Funding Number: RFA HS 17 011 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Alcohol-Induced Effects on Tissue Injury and Repair (R21) Apply for PA 17 296 Funding Number: PA 17 296 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03) Apply for RFA AG 18 015 Funding Number: RFA AG 18 015 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Socioeconomic Disparities in Health and Mortality at Older Ages (R01) Apply for RFA AG 18 011 Funding Number: RFA AG 18 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for the Development of Vaccines and Immunophrophylactics Targeting Multiple Antimicrobial-Resistant Bacteria (R01) Apply for RFA AI 17 017 Funding Number: RFA AI 17 017 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 17 275", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.